| Bioactivity | Niraparib metabolite M1 is a metabolite of niraparib, and the latter one acts as a novel poly(ADP-Ribose) polymerase (PARP) inhibitor. | ||||||||||||
| Invitro | Niraparib metabolite M1 has the validation in plasma and urine for the support of clinical studies such as the mass balance study and the absolute bioavailability study[1]. | ||||||||||||
| Name | Niraparib metabolite M1 | ||||||||||||
| CAS | 1476777-06-6 | ||||||||||||
| Formula | C19H19N3O2 | ||||||||||||
| Molar Mass | 321.37 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. van Andel L, et al. Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Nov 19;1040:14-21 |
Niraparib metabolite M1
CAS: 1476777-06-6 F: C19H19N3O2 W: 321.37
Niraparib metabolite M1 is a metabolite of niraparib, and the latter one acts as a novel poly(ADP-Ribose) polymerase (PA
Data collection：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.